Sweden-based medical technology company Aerocrine has launched the NIOX VERO device, designed to measure the airway inflammation, such as asthma.
Aerocrine and Panasonic Healthcare have jointly developed the new fully portable hand-held point-of-care device for the measurement of fractional exhaled nitric oxide, a validated method for measuring allergic airway inflammation.
NIOX VERO is an upgraded version of the gold standard and includes onboard, rechargeable battery, upgraded software, wireless technology and patient journaling. It has a lifespan of five years or 15,000 tests.
The device, which received CE Mark approval, will be initially launched in the UK, Sweden and Germany in the fourth quarter of 2013, while in the remaining European countries in early 2014.
By using the NIOX VERO, physicians can have more objective insights into treatment efficacy and can better predict a patients’ response to therapy and the risk of an asthma relapse.
Physicians can also identify patient non-compliance with medications and can adjust the medication dose based on the needs of individual patients.
The new device also provides benefits to doctors in measuring the underlying inflammation, which causes asthma within a few minutes.